Diabetes and obesity are projected to be epidemic in the emerging markets where westernization has become mainstream. That’s why we are committed to recruiting and retaining patients for biopharmaceutical and medical device and diagnostic studies in both these emerging markets and in more traditional areas.

Chiltern has a team of endocrinologists, nephrologists and other medical professionals who are familiar with the natural history of endocrine and metabolic diseases — adding support and value to your project with their expertise and leadership. Working as a cross-functional group, the team collaborates with you to provide advice from medical, operational, regulatory and cost-efficiency perspectives. Our staff has the clinical expertise, global experience and resources necessary to manage specialized indications and populations such as those in the endocrine and metabolic market, leading to better patient experiences, improved clinical outcomes and expedited regulatory approvals.

Chiltern’s diagnostic experience includes genetic sequencing and biomarker development; in vitro diagnostic (IVD) development including companion diagnostics; numerous radiological and imaging modalities development (imaging); mobile medical applications (MMA) and MMA-diagnostic medical device research across numerous therapeutic areas, including endocrinology.
Over the last five years, Chiltern has conducted a total of 92 endocrine & metabolic studies.

Endocrine & Metabolic

Investigators
Patients
Countries
Total Studies

Top Endocrine & Metabolic Indications From the Past Five Years

  • Diabetes companion devices
  • Diabetes complications
    • Diabetic foot ulcers
    • Diabetic nephropathy
    • Diabetic neuropathy
    • Macular edema
  • Diabetes diagnostic
  • Diabetes type 1
  • Diabetes type 2
  • Hyponatremia
  • Hypophosphatasia
  • Male hypogonadism
  • Molybdenum cofactor deficiency
  • Obesity
  • Renal disease (CKD and ESRD)

Let us help you reach your program’s goals with a comprehensive range of collaborative services: